BL0020 / Shanghai Best-Link Biosci - LARVOL DELTA

BL0020, a novel tumor microenvironment (TME)-targeting nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Updated results from the small cell lung cancer (SCLC) subset of a phase 1 study. (ASCO 2026) - P1 | "BL0020 monotherapy demonstrated a manageable safety profile and promising antitumor activity in patients with advanced SCLC who progressed after at least one prior platinum-based chemotherapy. The therapy showed a high response rate and potential for prolonged PFS compared with standard chemotherapy."

Biomarker • Clinical • Metastases • P1 data • Tumor microenvironment • Lung Cancer • Neutropenia • Oncology • Small Cell Lung Cancer • Solid Tumor

A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=33 | Not yet recruiting | Sponsor: Shanghai Best-Link Bioscience, LLC

New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy (clinicaltrials.gov) - P1/2 | N=48 | Not yet recruiting | Sponsor: Shanghai Best-Link Bioscience, LLC

First-in-human • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR

BL0020, a novel targeting tumor microenvironment (TME) nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Results from a phase I study (ESMO 2025) - "Conclusions BL0020 demonstrated a manageable safety profile and encouraging efficacy in advanced solid tumors, particularly in relapsed SCLC and malignant thymoma. Legal entity responsible for the study Shanghai Best-Link Bioscience, LLC."

Biomarker • Clinical • Metastases • P1 data • Tumor microenvironment • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Thymoma • Thymus Cancer

Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Shanghai Best-Link Bioscience, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer

Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Shanghai Best-Link Bioscience, LLC | Initiation date: Jul 2023 ➔ Oct 2023

Metastases • Trial initiation date • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer

Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Shanghai Best-Link Bioscience, LLC

Metastases • New P1 trial • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer